Skip to main content
Tech & Startups

London drug discovery start-up Boltz raises US$110 million

Bessemer Venture Partners led the Series A round, with Boltz planning to spend the money on computing, data and team expansion.

By Sofia TeixeiraPublished 1 min read

Computer workstations in a drug discovery research laboratory
Photo: Tech.eu

Boltz, a London start-up developing artificial intelligence models for drug discovery, has secured US$110 million in Series A financing. The funding comes less than a year after it emerged from stealth and follows a US$28 million seed round at the beginning of the year.

Bessemer Venture Partners led the investment. Returning backers included Andreessen Horowitz, Amplify Partners, Zetta Venture Partners and Obvious Ventures, while Greycroft, F-Prime Capital, Hummingbird and Benchling joined as new investors.

The business originated at MIT in the US and is now based in London's King's Cross, where it employs 40 AI researchers. Boltz said the new capital would support investment in computing and data, alongside an expansion of its team.

Its software is designed to help pharmaceutical and biotechnology researchers develop drug candidates and select those to test in laboratories. Its models predict the structures formed when proteins and drug candidates bind, estimate binding strength and propose molecules for a chosen target.

Boltz develops open-source models as well as models available through its platform and API. It earns revenue from partnerships and access to those tools, and has announced collaborations with Pfizer, GSK, Takeda and Bristol Myers Squibb.